Drug intelligence / Profile preview

gold-198 nanoparticle depot

Development stage
Preclinical
Lead developer
University of Toronto
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
Administration
Intratumoral
01

Overview

gold-198 nanoparticle depot (also known as [198Au]AuNPD) is a preclinical-stage intratumorally administered radiation nanomedicine being developed by researchers at the University of Toronto, McMaster University, and the University Health Network. It consists of gold-198 (198Au)-labeled gold nanoparticles packaged into a biodegradable calcium alginate seed (nanodepot). Gold-198 is a beta-particle emitter (t1/2 = 2.7 days, Eβmax = 0.96 MeV) that delivers a high, localized, and conformal radiation dose to the tumor tissue, minimizing exposure to surrounding healthy organs. The nanodepot is designed for local brachytherapy-like insertion. In preclinical models of triple-negative breast cancer (TNBC), the gold-198 nanoparticle depot has been evaluated alone and in combination with chemotherapeutic agents like doxorubicin or immune checkpoint inhibitors like atezolizumab, demonstrating significant inhibition of primary tumor growth and improvement in median survival.

Other names
198Au-labeled gold nanoparticle depotgold-198 labeled gold nanoparticle depotgold198 labeled gold nanoparticle depotgold 198 labeled gold nanoparticle depotgold-198 nanodepotgold198 nanodepotgold 198 nanodepot[198Au]-gold nanoparticle depot
02

Identity

Drug type
Radiopharmaceuticals
Originator
University of Toronto
Modality
Antibody-Based TherapeuticsAntibody-Radionuclide ConjugatesNanoparticles
Synonyms and codes
198Au-NPD
03

Pharmacology

Targets

Route
Intratumoral
04

Development

IndicationHighest phaseStatus
triple-negative breast cancer (TNBC) / hormone-receptor-negative, HER2-negative breast cancer (HR-/HER2-)PreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • University of TorontoOriginator · Lead developer
07

Competitive landscape

Drugs on the same target
280
Drugs in the lead indication
722

Lead indication: triple-negative breast cancer (TNBC) / hormone-receptor-negative, HER2-negative breast cancer (HR-/HER2-)

Most advanced in the lead indication

  1. amifostineApproved
  2. bleomycinApproved
  3. bleomycin A2Approved
  4. carboplatinApproved
  5. dacarbazineApproved

Beyond the preview

Go deeper on gold-198 nanoparticle depot.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gold-198 nanoparticle depot.

Work on gold-198 nanoparticle depot? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call